Jci_page_head_homepage_01 Jci_page_head_homepage_02
This page
  • E-mail this article

E-mail this article

Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia
Brian J. Druker, Nicholas B. Lydon
Published in Volume 105, Issue 1
J Clin Invest. 2000; 105(1):3 doi:10.1172/JCI9083
Full text | PDF

Recipient's email

Your name

Your e-mail

Comments

Cancel and return to article
Copyright © 2012 American Society for Clinical Investigation.
The JCI is the publication of the ASCI, an honor society of physician-scientists.
Copying, redistribution, and other usage policies